CLL
From the Journals
RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patients
Adverse events were largely seen during the first year of treatment and decreased over time.
From the Journals
Combo treatment yields MRD-negative remissions in CLL
Researchers with the German CLL Study Group said the combination of obinutuzumab plus venetoclax achieved fast responses.
From the Journals
Caution urged over real-world bleeding risk with ibrutinib
Ibrutinib was linked to an almost 20-fold increased risk of major bleeding in blood cancer patients taking concomitant antiplatelet and...
From the Journals
New chronic lymphocytic leukemia guidelines from the UK
The updated guidelines call for assessing TP53 mutations and deletions before each line of therapy.
From the Journals
Isavuconazole resolved invasive fungal disease in patients on ibrutinib
Four of eight patients experienced clinical and radiographic resolution; three improved.
From the Journals
Ibrutinib stacks up well on safety in pooled analysis
The study looked at ibrutinib safety for CLL/SLL and MCL across four studies.
Conference Coverage
Ibrutinib/venetoclax shows early promise in relapsed CLL
STOCKHOLM – An ongoing study shows a high clinical response rate and acceptable safety profile with the chemotherapy-free targeted therapy...
Conference Coverage
Rapid venetoclax dose escalation aids relapsed CLL
STOCKHOLM – A hospital-based dose-escalation protocol got CLL patients up to the target dose of venetoclax in 12 days, versus 35 days with the...
Conference Coverage
Is CLL chemoimmunotherapy dead? Not yet
CHICAGO – Frontline use of chemoimmunotherapy is complicated.
News
FDA grants regular approval to venetoclax for CLL/SLL
The drug is indicated for patients with CLL or SLL, with or without 17p deletion, who have had at least one prior therapy.
Conference Coverage
Venetoclax plus ibrutinib yields encouraging MRD results in first-line CLL
CHICAGO – The drug combination was evaluated in a phase 2 study of patients with previously untreated CLL.